Adaptive Biotechnologies reported strong Q1 2026 results with revenue of $70.9 million, a 35% increase from the previous year, driven mainly by a 53% growth in its Minimal Residual Disease (MRD) business. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting growing adoption of its MRD platform in clinical testing and drug development. Despite a net loss of $20 million, the loss narrowed compared to last year, and adjusted EBITDA loss also improved. Adaptive Biotechnologies plans to sustain growth with multiple drivers and will provide further outlook details in an upcoming conference call.
Adaptive Biotechnologies announced it will separate its profitable Minimal Residual Disease (MRD) diagnostics business, which has grown significantly and reached profitability, from its Immune Medicine business, which focuses on AI-driven immune data...
Adaptive Biotechnologies announced a proposed private offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million. The proceeds will primarily repay the OrbiMed Purchase Agreement, repurchase up to $2...
Harvest Investment Services has sold 356,000 shares of Adaptive Biotechnologies, totaling approximately $5.7 million. This significant sale may impact the stock's market perception and price. Investors should watch for any further moves by major shar...
